Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

  • STATUS
    Recruiting
  • End date
    Sep 30, 2024
  • participants needed
    18
  • sponsor
    AIDS Malignancy Consortium
Updated on 8 April 2021
remission
stem cell transplantation
immunodeficiency
hodgkin's disease
cytarabine
ejection fraction
melphalan
tenofovir
emtricitabine
hepatitis
efavirenz
truvada
direct bilirubin
atazanavir
etoposide
burkitt's lymphoma
follicular lymphoma
carmustine
mantle cell lymphoma
zidovudine
HIV Vaccine
t-cell lymphoma
immune globulin
indinavir
enzyme-linked immunosorbent assay
hiv-1 infection
raltegravir
combivir
prothrombin time (pt)

Summary

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.

Description

PRIMARY OBJECTIVES:

I. Safety, defined as timely engraftment (the collective establishment of a persistent absolute neutrophil count of at least 500 cells/mm^3 and platelet count of 20,000 cells/mm^3 without transfusion for 3 consecutive days) at one month post transplant, in the absence of any study candidate specific grade 3 and 4 non-hematopoietic organ toxicity or any clonal expansion.

II. Efficacy of the candidate product, defined as establishment of > 5% mononuclear blood cells expressing anti-HIV genes in the peripheral blood at 3 months post-transplant.

SECONDARY OBJECTIVES:

I. To determine the presence, quantity, and duration of gene modified HIV-1 resistant peripheral blood cells and gut mucosal immune cells.

II. To study the integration sites of vector sequences in circulating cells. III. To study progression-free survival. IV. To study overall survival. V. To study complete response rate and duration. VI. To study partial response rate and duration. VII. To study time to neutrophil engraftment (first of 3 consecutive days of absolute neutrophil count [ANC] > 500 cells/mm^3).

VIII. To study time to platelet engraftment (first of 3 consecutive days of platelets > 20,000 cells/mm^3 without platelet transfusions 7 days prior).

IX. To study hematologic function at day 100 (ANC > 1500, hemoglobin [Hb] > 10 g/dl without transfusion and platelets > 100,000) X. To study cluster of differentiation (CD)4 recovery at the conclusion of the trial.

XI. To study safety in terms of toxicities, infections, transfusions, and infusion-related reactions.

XII. To study HIV-1 viral load over time. XIII. To study persistence of vector-transduced cells over time.

TERTIARY OBJECTIVES:

I. To evaluate the presence and the magnitude of expansion of HIV-1 resistant immune cells in the peripheral blood and gut mucosa of transplanted participants, subsequent to withholding anti-retroviral therapy (ART).

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine twice daily (BID) on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.

After completion of study treatment, patients are followed up at days 7, 14, 21, 28, 42, 60, 90, 120, 180, 240, 300, 360, 420, 480, 520, 600, 660, and 720, and then yearly for at least 15 years.

Details
Condition HIV infection, Immunoblastic sarcoma, Immunodeficiency, Peripheral T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Adult Hodgkin Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma, Recurrent Burkitt Lymphoma, Stage III Follicular Lymphoma, Stage IV Follicular Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Primary Immunodeficiency Disorders, Recurrent Adult Non-Hodgkin Lymphoma, HIV Infections, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, human immunodeficiency virus, hiv disease, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma
Treatment laboratory biomarker analysis, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, carmustine, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Clinical Study IdentifierNCT02797470
SponsorAIDS Malignancy Consortium
Last Modified on8 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 19 yrs?
Gender: Male or Female
Do you have any of these conditions: Stage IV Mantle Cell Lymphoma or Recurrent Burkitt Lymphoma or Immunodeficiency or Stage IV Follicular Lymphoma or Recurrent Adult Hodgkin Lymphoma or...?
Do you have any of these conditions: Stage III Follicular Lymphoma or HIV infection or Recurrent Adult Non-Hodgkin Lymphoma or Stage III Mantle Cell Lymphoma or Immunoblastic sarcoma or S...?
Do you have any of these conditions: Recurrent Burkitt Lymphoma or hiv disease or Stage IV Follicular Lymphoma or Stage IV Mantle Cell Lymphoma or human immunodeficiency virus or Recurren...?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or Stage IV Mantle Cell Lymphoma or Stage IV Follicular Lymphoma or Immunodeficiency or hiv disease or Recurrent Follicular...?
Do you have any of these conditions: Recurrent Burkitt Lymphoma or Stage IV Mantle Cell Lymphoma or Stage IV Follicular Lymphoma or Stage III Mantle Cell Lymphoma or HIV Infections or Pri...?
Do you have any of these conditions: HIV Infections or Recurrent Adult Hodgkin Lymphoma or Immunoblastic sarcoma or Primary Immunodeficiency Disorders or Peripheral T-Cell Lymphoma or Imm...?
Inclusion criteria associated with type and status of lymphoma
Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, meeting one of the following criteria (timeline 4 months prior to start of trial)
In partial remission
Relapsed after initial complete remission
Failed induction therapy, but responds to salvage therapy (i.e., chemosensitive disease)
In complete remission with high-risk features as specified by the International Prognostic Index
Biopsy-proven advanced stage follicular lymphoma, that have failed at least two lines of therapy multi-agent chemotherapy, but responds to salvage therapy (i.e., chemosensitive disease) (timeline 4 months prior to start of trial)
Biopsy-proven advanced stage mantle cell lymphoma with proliferation-related Ki-67 antigen (Ki-67) > 10% in first complete remission (timeline 4 months prior to start of trial)
Biopsy-proven Hodgkin's lymphoma, meeting one of the following criteria (timeline 4 months prior to start of trial)
In first, or greater relapse after initial complete remission
In partial remission
Failed induction therapy, but responds to salvage therapy (i.e., chemosensitive disease)
Biopsy-proven Burkitt's lymphoma, meeting one of the following criteria (timeline 4 months prior to start of trial)
In second complete remission after relapse following initial complete remission
Failed induction therapy, but responds (very good partial remission, complete remission, or near complete remission) to salvage therapy (i.e., chemosensitive disease)
Biopsy proven plasmablastic lymphomas, or peripheral T cell lymphoma (with the exception of anaplastic lymphoma kinase positive [ALK+] type in first or second complete remission) (timeline 4 months prior to start of trial)
INCLUSION CRITERIA ASSOCIATED WITH HIV-1 STATUS
HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection
Must be on a multi-drug anti-HIV regimen (excluding zidovudine [AZT, ZDV, Retrovir, or agents containing zidovudine (e.g., Combivir and Trizivir)], and efavirenz [Sustiva, or agents containing efavirenz (e.g., Atripla)]), and have an HIV-1 viral load < 50 copies/mL by reverse transcriptase-polymerase chain reaction (RT-PCR) at the time of study enrollment; participants on zidovudine [AZT, ZDV, Retrovir; including Combivir and Trizivir] and efavirenz [Sustiva; including Atripla] must switch to an alternative regimen without anticipated drug-drug interactions or myelosuppressive properties based on known viral resistance patterns and/or ART history, such as raltegravir and Truvada (emtricitabine and tenofovir) at least two weeks prior to the transplant
Participants with CD4 counts > 50/microL are eligible for this study if their viral load is < 50 copies/mL by reverse transcription polymerase chain reaction (RT-PCR) since majority of the participants have received aggressive chemotherapy that can potentially decrease the CD4 counts despite the ART therapy; timeline: within 3 weeks prior to start of trial
GENERAL INCLUSION CRITERIA (TIMELINE: 8 WEEKS PRIOR TO START OF TRIAL, UNLESS OTHERWISE SPECIFIED)
Karnofsky performance status of 70-100%; Eastern Cooperative Oncology Group (ECOG) performance status =< [2]
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) >= 2.5 times upper limit of normal (ULN)
Serum bilirubin =< 2.5 times ULN except for participants who are on atazanavir or indinavir, provided that the participant's direct bilirubin is within normal institutional limits
Participants who are hepatitis C virus antibody positive, or hepatitis B virus surface antigen positive must be free of clinical evidence of cirrhosis as determined by the principal investigator in consultation with the gastroenterology service; timeline: within 3 weeks prior to start of trial
Participants with hepatitis B should be on appropriate anti-viral therapy at the time of the transplant, and their viral load should be under control; timeline: within 3 weeks prior to start of trial
Serum creatinine =< 2 times ULN; timeline: within 3 weeks prior to start of trial
Creatinine clearance >= 60 mL/min; timeline: within 3 weeks prior to start of trial
Prothrombin time (PT)/partial thromboplastin time (PTT) =< 2 times normal; timeline: within 3 weeks prior to start of trial
Forced expiratory volume in 1 second (FEV-1) or diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% predicted; timeline: within 4 weeks prior to start of trial
Left ventricular ejection fraction (LVEF) >= 50% by 20-dimensional (20D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan; timeline: within 4 weeks prior to start of trial
Not pregnant or nursing, with negative pregnancy test; timeline: within 3 weeks prior to start of trial
Life expectancy of greater than 3 months
Ability to understand and the willingness to sign a written informed consent document
Receipt of a stable ART regimen for at least 3 weeks prior to start of trial

Exclusion Criteria

Participants with > 5% involvement of bone marrow by malignant cells (either by manual count or flow cytometry) prior to stem cell collection
Participants with any abnormal cytogenetics in the bone marrow not related to the lymphoma, and not deemed to be constitutional
Participants with unexplained anemia, and/or thrombocytopenia
Participants with clear evidence of myeloproliferative disorders, or myelodysplastic disorders in the marrow
Presence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal)
Any history of HIV-1 associated encephalopathy
History of other acquired immune deficiency syndrome (AIDS)-related syndromes that are perceived to cause excessive risk for morbidity post-transplantation, as determined by the principal investigator
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
Active cytomegalovirus (CMV) retinitis, or other active CMV-related organ dysfunction
Relapse of pneumocystis carinii pneumonia within the past year
Intractable, severe diarrhea, defined as > 1.500 cc diarrheal fluid per day, or diarrhea causing persistent severe electrolyte abnormalities, or hypoalbuminemia
History of active myocardial ischemia, cardiomyopathy, uncontrolled dysrhythmia, or congestive heart failure within the last 6 months before the evaluation
Dementia of any kind
Seizures within the past 12 months
History of grade III hemorrhagic cystitis due to prior cyclophosphamide chemotherapy
History of other prior malignancy, except squamous cell carcinoma of the cervix or anus, superficial basal cell or squamous cell skin cancer, or other malignancy curatively treated more than 5 years ago
Active psychosocial condition that would hinder study compliance and follow-up
Any perceived inability to directly (and without the means of a legal guardian) provide informed consent
Any medical or physical contraindication, or other inability to undergo hematopoietic progenitor cell (HPC) collection
Participants who are receiving any other investigational agents
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study; breastfeeding should be discontinued; these potential risks may also apply to other agents used in this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note